A Phase 2 randomised study to establish efficacy, safety and dosing of a novel oral cathepsin C inhibitor, BI 1291583, in adults with bronchiectasis: Airleaf

A Phase 2 randomised study to establish efficacy, safety and dosing of a novel oral cathepsin C inhibitor, BI 1291583, in adults with bronchiectasis: Airleaf

New therapies are needed to prevent exacerbations, improve quality of life and slow disease progression in bronchiectasis. Inhibition of cathepsin C (CatC) activity has the potential to decrease activation of neutrophil-derived serine proteases in patients with bronchiectasis, thereby reducing airwa...

Full description

Bibliographic Details
Main Authors: James D. Chalmers, Abhya Gupta, Sanjay H. Chotirmall, April Armstrong, Peter Eickholz, Naoki Hasegawa, Pamela J. McShane, Anne E. O'Donnell, Michal Shteinberg, Henrik Watz, Anastasia Eleftheraki, Claudia Diefenbach, Wiebke Sauter
Format: Article
Language:English
Published: European Respiratory Society 2023-06-01
Series:ERJ Open Research
Online Access:http://openres.ersjournals.com/content/9/3/00633-2022.full

Internet

http://openres.ersjournals.com/content/9/3/00633-2022.full

Similar Items